Page last updated: 2024-11-05

trimetazidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trimetazidine is a medication primarily used to treat angina, a type of chest pain caused by reduced blood flow to the heart. It belongs to a class of drugs known as anti-anginal agents. The compound's mechanism of action involves inhibiting the enzyme fatty acid oxidation. This results in a shift towards glucose metabolism in the heart, reducing the heart's need for oxygen, and thus alleviating chest pain. Trimetazidine is synthesized in a multi-step process involving various chemical reactions. Its effectiveness in treating angina has been well-established through numerous clinical trials. Researchers are also studying its potential benefits in other conditions such as Alzheimer's disease and Parkinson's disease. These studies aim to explore the compound's neuroprotective properties and its potential to improve cognitive function. Trimetazidine's importance stems from its ability to provide relief for patients with angina, as well as its potential for future applications in treating other diseases. Its unique mechanism of action and its relative safety profile make it a subject of ongoing research.'

Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21109
CHEMBL ID203266
CHEBI ID94789
SCHEMBL ID230374
MeSH IDM0021987

Synonyms (74)

Synonym
PRESTWICK3_000549
smr000814701
MLS001331735
EN300-14439
BB 0220635
BRD-K88366685-300-03-7
1-(2,3,4-trimethoxy-benzyl)-piperazine
BAS 06612844
BPBIO1_000657
BSPBIO_000597
cas-13171-25-0
NCGC00016697-01
OPREA1_279550
PRESTWICK2_000549
STK315643
piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-
trimetazidine [inn:ban:dcf]
trimetazidinum [inn-latin]
trimetazidina [inn-spanish]
trimetazidine
einecs 225-690-2
1-(2,3,4-trimethoxybenzyl)piperazine
SPBIO_002518
PRESTWICK1_000549
PRESTWICK0_000549
smr000674573
MLS001240268 ,
NCGC00016697-02
AKOS000308094
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine
trimetazidine (inn)
D08642
5011-34-7
dilatan (tn)
CHEMBL203266
A837947
A827982
BBL013084
HMS2230L07
vasorel
preductal mb
4-(2,3,4-trimethoxybenzyl)piperazine
unii-n9a0a0r9s8
preductal
trimetazidina
trimetazidinum
n9a0a0r9s8 ,
trimetazidine [mi]
trimetazidine [inn]
trimetazidine [who-dd]
S5779
HMS3374D04
SCHEMBL230374
1-(2,3,4-trimethoxyphenyl)methylpiperazine
1-(2,3,4-trimethoxy benzyl)piperazine
1-(2,3,4-trimethoxyphenylmethyl)piperazine
DTXSID2048531
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine;hydrochloride
bdbm80613
cid_9926449
1-(2,3,4-trimethoxybenzyl)piperazine;hydrochloride
piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-
1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride
DB09069
mfcd00868263
CHEBI:94789
Z99601262
BCP16534
HY-B0968A
127881-54-3
Q674703
BRD-K88366685-300-04-5
CS-0099250
SB75326

Research Excerpts

Overview

Trametazidine (TMZ) is an anti-anginal drug with anti-oxidant and anti-inflammatory properties. Trimetazidine is a metabolic anti-ischemic agent, which increases the tolerance of cardiomyocytes to ischemia.

ExcerptReferenceRelevance
"Trimetazidine (TMZ) is a well-known anti-ischemic agent used for the treatment of angina pectoris. "( Trimetazidine an emerging paradigm in renal therapeutics: Preclinical and clinical insights.
Bagang, N; Gupta, K; Mehra, K; Pandey, S; Singh, G, 2021
)
3.51
"Trimetazidine is a metabolic agent that has been demonstrated to provide protective effects in myocardial ischemia."( Trimetazidine Alleviates Postresuscitation Myocardial Dysfunction and Improves 96-Hour Survival in a Ventricular Fibrillation Rat Model.
Chen, B; Dai, C; Li, J; Li, Y; Qi, Y; Wang, J, 2022
)
2.89
"Trimetazidine (TMZ) is an anti-anginal drug with anti-oxidant and anti-inflammatory properties."( Trimetazidine attenuates cyclophosphamide-induced cystitis by inhibiting TLR4-mediated NFκB signaling in mice.
Arıcı, T; Barut, EN; Engin, S; Kadıoğlu, M; Kerimoğlu, G; Sezen, SF; Soysal, AÇ; Yaşar, YK, 2022
)
2.89
"Trimetazidine (TMZ) is a metabolic anti-ischemic drug that blocks the activity of long-chain 3-ketoacyl CoA thiolase leading to the inhibition of fatty acid oxidation."( Insights into the therapeutic outcomes of trimetazidine/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model.
Abdeljalil, SM; Elghazaly, H; Tolba, MF; Wahdan, SA, 2023
)
1.9
"Trimetazidine is an antianginal agent with a unique mechanism of action that regulates myocardial energy metabolism and might have a beneficial effect in preventing HF in patients undergoing myocardial revascularization."( Impact of Trimetazidine on the Incident Heart Failure After Coronary Artery Revascularization.
Chang, J; Choi, HY; Hong, SP; Jin, ES; Kong, MG; Kwon, SS; Park, GM; Park, RW; Park, S, 2023
)
2.03
"Trimetazidine is a piperazine-derived metabolic agent. "( The cystathionine γ-lyase/hydrogen sulfide pathway mediates the trimetazidine-induced protection of H9c2 cells against hypoxia/reoxygenation-induced apoptosis and oxidative stress.
Liu, C; Zheng, W, 2019
)
2.2
"Trimetazidine is a metabolic anti-ischemic agent, which increases the tolerance of cardiomyocytes to ischemia. "( Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial.
He, J; Jin, C; Li, Y; Luan, Y; Wang, M; Wu, L; Zhang, W, 2020
)
2.39
"Trimetazidine is an antianginal agent that improves energy metabolism of the ischaemic myocardium and might improve outcomes and symptoms of patients who recently had a PCI."( Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
Challeton, JP; Correges, A; Danchin, N; Ferrari, R; Ford, I; Fox, K; Tendera, M; Widimský, P, 2020
)
1.59
"Trimetazidine (TMZ) is a type of anti-ischemic drug developed in recent years, which can reduce the incidence of CIN."( Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency.
Fu, H; Fu, N; Fu, X; Li, W; Liu, X; Yang, S; Zeng, Z; Zhang, H; Zhang, J; Zhang, P; Zhang, X, 2021
)
2.79
"Trimetazidine (TMZ) is an anti-ischemic agent that can inhibit the fatty acid oxidation. "( Trimetazidine alone or in combination with gemcitabine and/or abraxane decreased cell viability, migration and ATP levels and induced apoptosis of human pancreatic cells.
Atlı Şekeroğlu, Z; Aydın, B; Işık, S; Şekeroğlu, V, 2021
)
3.51
"Trimetazidine (TMZ) is an anti-ischemic drug, which inhibits cellular oxidative stress, eliminates oxygen-free radicals, and improves lipid metabolism."( Trimetazidine Protects from Mercury-Induced Kidney Injury.
Bulacio, RP; Hazelhoff, MH; Torres, AM, 2021
)
2.79
"Trimetazidine is a less well known anti-anginal drug that controls myocardial ischaemia through intracellular metabolic changes."( WITHDRAWN: Trimetazidine for stable angina.
Ciapponi, A; Harrison, J; Pizarro, R, 2017
)
1.57
"Trimetazidine (TMZ) is a metabolic agent with significant anti-ischemic properties. "( Trimetazidine in the Prevention of Tissue Ischemic Conditions.
Giannitsi, S; Kallistratos, MS; Manolis, AJ; Poulimenos, LE; Tsinivizov, P, 2019
)
3.4
"Trimetazidine (TMZ) is an anti-ischemic drug. "( The Effects of Trimetazidine on QT-interval Prolongation and Cardiac Hypertrophy in Diabetic Rats.
Ahangarpour, A; Badavi, M; Dianat, M; Mard, SA; Ramezani-Aliakbari, F, 2019
)
2.31
"Trimetazidine (TMZ) is a metabolic modulator that shifts substrate utilization from fatty acid to carbohydrates, thereby, increasing myocardial glucose oxidation and improving myocardial ischemia. "( Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.
Ambesh, P; Garg, N; Goel, PK; Kapoor, A; Kashyap, S; Kazmi, DH; Khanna, R; Kumar, S; Sinha, A; Tewari, S, 2018
)
2.21
"Trimetazidine (TMZ) is a widely used drug exerting cardioprotective effects against ischemic heart disease through a number of mechanisms in conditions of oxidative stress. "( Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and Akt/eNOS signaling pathways.
Cheng, B; Li, Y; Liu, L; Liu, Y; Qi, B; Wang, Q; Wu, Q, 2013
)
2.09
"Trimetazidine (TMZ) is a clinically effective antianginal agent that selectively inhibits long-chain 3-ketoacyl CoA thiolase, reducing fatty acid oxidation and stimulating glucose oxidation."( Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry.
Ahn, EY; Choi, JH; Chun, KJ; Jeong, MH; Kim, CH; Kim, EJ; Kim, J; Kim, JH; Kim, JS; Lee, SH; Park, YH; Yu, DG, 2013
)
1.5
"Trimetazidine (TMZ) is a metabolic agent used in cardiology for more than 40 years. "( Trimetazidine and cardioprotection: facts and perspectives.
Andrikopoulos, G; Manolis, A; Tsioufis, K, 2015
)
3.3
"Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a 'placebo drug' whose new side effects, such as Parkinsonian symptoms, outweigh its benefits. "( Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.
Banach, M; Chrusciel, P; Rysz, J, 2014
)
2.16
"Trimetazidine is an anti-ischemic agent with antioxidant activity. "( Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention.
Shehata, M, 2014
)
2.25
"Trimetazidine (TMZ) is a well-known anti-ischemic agent; however, its efficacy and mechanism of cardioprotection on coronary microembolization (CME) are largely unknown. "( Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a Swine model of coronary microembolization.
Li, L; Liu, T; Liu, YC; Su, Q; Tang, ZL, 2015
)
3.3
"Trimetazidine is an anti-ischemic drug that might reduce incidence of CIN, but current data are inconclusive."( Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
Annapureddy, N; Benjo, AM; Javed, F; Konstantinidis, I; Kumbala, D; Nadkarni, GN; Pakanati, KC; Patel, A; Patel, RA; Simoes, PK; Yacoub, R, 2015
)
2.58
"Trimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. "( [Thiotriazoline in the Treatment of Stable Angina Pectoris of II-III Functional Class].
Chumak, BA; Filippov, AE; Kadin, DV; Shustov, SB, 2015
)
1.86
"Trimetazidine (TMZ) is an anti-anginal drug that has been widely used in Europe and Asia. "( The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Chen, JM; Guo, HM; Huang, H; Kuznicki, M; Li, J; Liu, Z; Quan, N; Sun, W; Wang, L; Yang, H; Zheng, S; Zhu, P; Zhuang, J, 2016
)
2.18
"Trimetazidine is a piperazine-derived metabolic agent, which exerts cell protective effects and has been reported to be efficient in the treatment of chronic stable angina pectoris. "( Trimetazidine protects against cardiac ischemia/reperfusion injury via effects on cardiac miRNA‑21 expression, Akt and the Bcl‑2/Bax pathway.
Bai, J; Liu, D; Luo, H; Ma, N; Qiao, C; Zhang, W; Zhang, X, 2016
)
3.32
"Trimetazidine (TMZ) is a type of anti-ischemic drug developed in recent years, which can significantly reduce the incidence of CIN."( Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis.
Dai, W; Guo, W; Li, H; Li, L; Lu, H; Su, Q; Yang, H; Ye, Z, 2017
)
1.5
"Trimetazidine (TMZ) is an anti-ischemic agent which has been used for years as an effective anti-anginal agent in cardiac patients. "( Effects of trimetazidine on crush injury of the sciatic nerve in rats: a biochemical and stereological study.
Altug, ME; Bal, R; Keleş, ON; Kontaş, T; Serarslan, Y; Unal, B; Unal, D, 2009
)
2.19
"Trimetazidine is an anti-ischemic agent with cardioprotective effects. "( Trimetazidine may protect the myocardium during cardiac surgery.
Cerrahoglu, M; Eserdag, M; Iskesen, I; Kurdal, AT; Sirin, BH, 2009
)
3.24
"Trimetazidine is an anti-ischemic metabolic agent which improves myocardial glucose utilization. "( The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy.
Cui, LQ; Maharaj, P; Narraindoo, S; Tang, YS; Yin, XG; Zhang, J; Zhao, P, 2013
)
2.19
"Trimetazidine (TMZ) is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. "( Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study.
Malorni, W; Perrone-Filardi, P; Rosano, GM; Spoletini, I; Vitale, C; Volterrani, M, 2013
)
2.21
"Trimetazidine is an anti-ischemic agent which is frequently prescribed as a prophylactic treatment of episodes of angina pectoris and as a symptomatic treatment of vertigo and tinnitus. "( Protective effect of trimetazidine in a model of ischemia-reperfusion in the rat retina.
Espinasse-Berrod, MA; Frasson Correa De Silva, M; Jacquet, A; Lucien, A; Mohand-Said, S; Sahel, J,
)
1.89
"Trimetazidine acts as an effective antianginal clinical agent by modulating cardiac energy metabolism. "( The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Binding, P; Fairman, DA; Haddock, PS; Karran, EH; MacInnes, A; Phelan, A; Rhodes, Ja; Wyatt, MJ, 2003
)
2.08
"Trimetazidine is a drug with cardioprotective properties used in coronary artery disease. "( Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: a preliminary study.
Ambard, MJ; Bermúdez, FA; Bermúdez, VJ; Cano, C; Contreras, F; Escalona, D; Medina, MT; Souki, AJ; Velasco, M,
)
3.02
"Trimetazidine (TMZ) is a cellular anti-ischemic agent, which has been studied in clinical and experimental investigations, and was shown to have protective affects against myocardial ischemia and reperfusion injury. "( Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia.
Dernek, S; Ikizler, M; Kural, T; Sevin, B, 2003
)
3.2
"Trimetazidine is an anti-ischemic drug whose cytoprotective mechanisms are not yet fully understood (but until now mainly related to the trimetazidine-induced "metabolic shift" from lipid beta-oxidation to glucose aerobic oxidation). "( Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
Duarte, AI; Gonçalves, LM; Monteiro, P; Moreno, A; Providência, LA, 2004
)
2.09
"Trimetazidine is a widely used anti-ischemic agent, but its effect on myocardial preconditioning in anesthetized animals has not been investigated. "( Effects of trimetazidine on myocardial preconditioning in anesthetized rats.
Celik, A; Demiryürek, AT; Demiryürek, S; Kara, AF; Tarakçioğlu, M, 2004
)
2.16
"Trimetazidine is an anti-ischemic agent that improves the myocardial metabolism and that can be especially useful in the ischemic myocardium of diabetic patients."( [A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study].
Gil Polo, B; Maicas Bellido, C; Rodríguez Padial, L; Velázquez Martín, M, 2005
)
1.36
"Trimetazidine is a less well known anti-anginal drug that controls myocardial ischaemia through intracellular metabolic changes."( Trimetazidine for stable angina.
Ciapponi, A; Harrison, J; Pizarro, R, 2005
)
2.49
"Trimetazidine (TMZ) is an antioxidant agent used to protect grafts from ischemia-reperfusion injury."( Effect of trimetazidine on the nucleotide profile in rat kidney with ischemia-reperfusion injury.
Chlubek, D; Ciechanowski, K; Domanski, L; Olszewska, M; Pawlik, A; Safranow, K; Sulikowski, T; Urasinska, E, 2006
)
1.46
"Trimetazidine is an anti-ischemic agent that is used to treat angina and it has cardioprotective effects without inducing any significant hemodynamic changes. "( Trimetazidine reduces oxidative stress in cardiac surgery.
Cerrahoglu, M; Iskesen, I; Nazli, Y; Saribulbul, O; Sirin, H; Var, A, 2006
)
3.22
"Trimetazidine is a widely used anti-ischemic agent, but effects of its chronic treatment on myocardial preconditioning in anesthetized animals have not been investigated. "( Effects of chronic trimetazidine treatment on myocardial preconditioning in anesthetized rats.
Celik, A; Demiryürek, AT; Demiryürek, S; Kara, AF; Tarakçioğlu, M, 2006
)
2.1
"Trimetazidine is a new metabolic antiischemic agent, which increases the tolerance of cardiomyocytes to ischemia. "( [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
Barkhudarian, AL; Sisakian, AS; Torgomian, AL, 2006
)
2.12
"Trimetazidine (TMZ) is an anti-ischemic drug."( Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: early and long-term effects in a pig kidney model.
Carretier, M; Doucet, C; Eugene, M; Favreau, F; Goujon, JM; Hauet, T; Hebrard, W; Jayle, C; Mauco, G; Tillement, JP; Zhang, K, 2007
)
1.34
"Trimetazidine (TMZ) is a drug able to restore the metabolic balance between fatty acid and glucose oxidation in ischemic myocardial cells."( Trimetazidine protective effect against ischemia-induced susceptibility to ventricular fibrillation in pigs.
Bescond-Jacquet, A; Bricca, G; Bui-Xuan, B; Descotes, J; Tabib, A; Timour, Q; Tsibiribi, P; Vaillant, F, 2008
)
2.51
"Trimetazidine (TMZ) is an anti-ischemic and antioxidant agent used to protect grafts from I/R injury."( Effect of trimetazidine on xanthine oxidoreductase expression in rat kidney with ischemia--reperfusion injury.
Adler, G; Chlubek, D; Ciechanowicz, A; Ciechanowski, K; Domanski, L; Dziedziejko, V; Pawlik, A; Safranow, K; Sulikowski, T, 2008
)
1.47
"Trimetazidine (TMZ) is an effective and well-tolerated antianginal drug that possesses protective properties against ischemia-induced heart injury. "( Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.
Onay-Besikci, A; Ozkan, SA, 2008
)
3.23
"Trimetazidine is a cytoprotective anti-ischaemic agent whose antianginal efficacy has been demonstrated in monotherapy versus placebo and versus reference products, and in combination with beta-blockers and nifedipine. "( [Value of the combination of trimetazidine (Vastarel 20 mg) with diltiazem (Tildiem 60 mg) in stable effort angina. A double-blind versus placebo multicenter study].
Lévy, S, 1995
)
2.03
"Trimetazidine (TMZ) is an anti-ischemic compound whose precise mode of action is unknown, although several studies have suggested a metabolic effect, and there have been reports of protection of mitochondria against oxidative stress damage. "( Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion.
Hue, L; Maisin, L; Veitch, K, 1995
)
3.18
"Trimetazidine is an agent which could prevent or limit the deleterious effects of free radicals on the myocardium and could, therefore, improve the prognosis for patients with acute myocardial infarction (MI) receiving thrombolytic therapy."( Free radicals, reperfusion and myocardial infarction therapy: European Myocardial Infarction Project--free radicals pilot study. EMIP-FR Pilot Study Group.
, 1993
)
1.01
"Trimetazidine (TMZ) is an anti-ischemic compound devoid of hemodynamic effects. "( Trimetazidine increases phospholipid turnover in ventricular myocyte.
Grynberg, A; Lucien, A; Sentex, E; Sergiel, JP, 1997
)
3.18
"1. Trimetazidine is an anti-ischaemic drug effective in different experimental models but its mechanism of action is not fully understood. "( Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore.
Carrupt, PA; Crevat, A; Elimadi, A; Morin, D; Sapena, R; Testa, B; Tillement, JP, 1998
)
1.2
"Trimetazidine is an antiischemic drug protecting the myocardium from ischemic damage through the preservation of mitochondrial oxidative metabolism, without any hemodynamic effect. "( Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium.
Campa, PP; Ciavolella, M; Greco, C; Scopinaro, F; Tanzilli, G; Tavolaro, R,
)
1.96
"Trimetazidine is an anti-ischemic compound devoid of hemodynamic effect, which was recently suspected to induce cardioprotection at the cellular level by a mechanism involving lipid metabolism. "( Is the cytoprotective effect of trimetazidine associated with lipid metabolism?
Grynberg, A; Lucien, A; Sentex, E; Sergiel, JP, 1998
)
2.03
"Trimetazidine is an effective and well tolerated anti-ischaemic agent which, in addition to providing symptom relief and functional improvement in patients with angina pectoris, has a cytoprotective action during ischaemia. "( Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.
McClellan, KJ; Plosker, GL, 1999
)
3.19
"Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties. "( The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Kantor, PF; Kozak, R; Lopaschuk, GD; Lucien, A, 2000
)
2.07
"Trimetazidine is a well tolerated and efficient antianginal agent, that experimentally reduces ischemia-reperfusion injuries, neutrophil infiltration, platelet aggregation and has antioxidant effects."( Trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction.
Beygui, F, 2000
)
2.47
"Trimetazidine is a well-established anti-ischemic drug, which has been used for long time in the treatment of pathological conditions related with the generation of reactive oxygen species. "( Trimetazidine protects low-density lipoproteins from oxidation and cultured cells exposed to H(2)O(2) from DNA damage.
Doulias, P; Galaris, D; Glantzounis, G; Lourida, E; Tselepis, A; Tsimoyiannis, E, 2001
)
3.2
"Trimetazidine is an anti-ischemic drug that restores the ability of ischemic cells to produce energy and reduces the generation of oxygen-derived free radicals."( Recipient treatment with trimetazidine improves graft function and protects energy status after lung transplantation.
Boehler, A; Dutly, A; Inci, D; Inci, I; Weder, W, 2001
)
1.34
"Trimetazidine is an anti-ischemic drug that restores the ability of the ischemic cells to produce energy and reduces the generation of oxygen-derived free radicals."( Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model.
Boehler, A; Dutly, A; Inci, I; Rousson, V; Weder, W, 2001
)
2.47

Effects

Trametazidine has a direct anti-ischaemic effect on the myocardium without altering the rate x pressure product or coronary blood flow. It has an original cytoprotective mode of action reducing oxygen demand.

Trimetazidine (TMZ) has potential benefits for the condition but has not yet been fully recognized. It has been shown to prevent the risk of contrast-induced nephropathy (CIN) in patients with renal dysfunction undergoing percutaneous coronary intervention (PCI)

ExcerptReferenceRelevance
"1. Trimetazidine has a direct anti-ischaemic effect on the myocardium without altering the rate x pressure product or coronary blood flow. "( Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
Cokkinos, D; Dargie, H; Detry, JM; Mathes, P; Pennaforte, S; Sellier, P, 1994
)
2.35
"Trimetazidine has an original cytoprotective mode of action reducing oxygen demand without altering heart activity."( [New concepts in the therapy of diabetic cardiopathies].
Pogátsa, G, 1997
)
1.02
"Trimetazidine has an anti-ischemic effect in angina pectoris. "( Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
Buxton, DB; Coyle, KB; Hansen, HW; Mody, FV; Mohiuddin, IH; Schelbert, HR; Singh, BN; Sumida, R, 1998
)
3.19
"Trimetazidine (TMZ) has potential benefits for the condition but has not yet been fully recognized."( Newly discovered molecules associated with trimetazidine on improvement of skeletal muscle function in aging: evidence from myoblasts and mice.
Fu, SH; Lin, JQ; Wang, JX; Yu, S; Zhang, YJ, 2022
)
1.71
"Trimetazidine has affirmative preventive properties in the chronic pancreatitis course."( Trimetazidine has Promising Preventive Effects on Experimental Chronic Pancreatitis Rat Model.
Çırak, Z; Kaplan, M; Karakaya, A; Küçükodacı, Z; Önal Taştan, Y; Tanoğlu, A; Yıldırım, M, 2022
)
2.89
"Trimetazidine has been reported to have potential benefits in patients with chronic heart failure (CHF). "( Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study.
Min, Z; Qiuhong, S; Ran, Z; Xuelu, L; Yong, M, 2022
)
2.5
"Trimetazidine has been shown to prevent the risk of contrast-induced nephropathy (CIN) in patients with renal dysfunction undergoing percutaneous coronary intervention (PCI). "( The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization.
Chen, J; He, P; He, W; Lian, X; Liu, Y; Tan, N; Zhan, H, 2019
)
2.32
"Trimetazidine has significant cardioprotective effects and improves endothelial dysfunction and myocardial injury."( Effect of trimetazidine on incidence of major adverse cardiac events in coronary artery disease patients undergoing percutaneous coronary intervention: A protocol for systematic review and meta-analysis.
Fang, Y; Zheng, YS; Zhu, K, 2020
)
1.68
"Trimetazidine (TMZ) has traditionally been used as an anti-ischaemic drug for coronary artery disease."( Trimetazidine ameliorates hindlimb ischaemic damage in type 2 diabetic mice.
Li, T; Shao, S; Xu, Q; Yang, Y, 2021
)
2.79
"Trimetazidine has been reported, in some studies, to be better tolerated than combined anti-anginal therapy; however it is not considered in published guidelines."( WITHDRAWN: Trimetazidine for stable angina.
Ciapponi, A; Harrison, J; Pizarro, R, 2017
)
1.57
"Trimetazidine has been described as a cellular anti-ischemic agent."( Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease.
El-Fekky, EM; El-Mawardy, RH; El-Serafy, AS; Ibrahim, TA,
)
2.3
"Trimetazidine (TMZ) has been shown to reduce angina symptoms and to increase exercise capacity in randomized clinical trials, but more extensive data would be useful to assess its effects in real-world clinical practice and in patients with different durations of disease."( The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study.
Glezer, M, 2018
)
2.24
"Trimetazidine (TMZ) has been demonstrated to have protective effects against myocardial ischemia/reperfusion (MI/R) injury. "( Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy.
Chang, G; Gao, L; Guo, X; Jiang, D; Li, G; Luo, X; Qin, S; Wang, L; Wu, S; Zhang, D, 2018
)
3.37
"Trimetazidine (TMZ) has been shown to optimize myocardial energy metabolism and is a common anti-ischemic agent. "( Trimetazidine attenuates high-altitude fatigue and cardiorespiratory fitness impairment: A randomized double-blinded placebo-controlled clinical trial.
Bian, S; Huang, L; Liu, C; Yang, J; Yu, J; Yu, S; Zhang, C; Zhang, J; Zhang, L, 2019
)
3.4
"Trimetazidine (TMZ) has been used as an anti-ischemic agent for angina pectoris, chorioretinal disturbances, and vertigo. "( Antipsychotic-like effect of trimetazidine in a rodent model.
Akseki, HS; Eliküçük, B; Erbaş, O; Taşkıran, D, 2013
)
2.12
"Trimetazidine has been shown to improve angina pectoris and left ventricular (LV) function in diabetic patients with ischaemic cardiomyopathy. "( Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind
Gao, F; Liu, Y; Ma, H; Ma, Q; Shen, H; Shi, D; Wang, Z; Xu, X; Yu, M; Zhang, J; Zhang, W; Zhao, Y; Zhou, Y; Zhou, Z, 2014
)
2.25
"Trimetazidine has multiple favorable effects on the cardiovascular system."( Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study.
Chen, J; Chen, Y; Han, Y; Jin, J; Liu, J; Tian, F; Wang, J; Zhou, S, 2014
)
1.43
"Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. "( Trimetazidine in conditions other than coronary disease, old drug, new tricks?
Cen, XJ; Ding, YH; Huang, DS; Jin, QY; Qian, LY; Zhu, XX; Zou, H, 2017
)
3.34
"Trimetazidine (TZM) has been shown to have anti-ischemia properties by optimizing ischemic myocardium metabolism. "( [Effects of trimetazidine on myocardial metabolism evaluated by PET-CT in patients with ischemic cardiomyopathy].
Chen, S; Jin, J; Lu, Q; Song, WZ; Wang, WY; Xie, HJ; Xu, GH; Zhong, P; Zhou, XF, 2008
)
2.17
"Trimetazidine has been shown to improve symptoms and ventricular function and to have a beneficial effect on the inflammatory profile and endothelial function in these patients."( Prognostic relevance of metabolic approach in patients with heart failure.
Barsotti, A; Di Napoli, P, 2009
)
1.07
"Trimetazidine (TMZ) has been described as a cellular anti-ischaemic agent."( Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram.
Ahmed, K; Ahsan, SA; Banerjee, SK; Bhuiyan, MM; Debnath, RC; Haque, SS; Joarder, AI; Mahmood, M; Rahman, F; Rahman, MM; Rokeya, B; Siddique, MA, 2012
)
2.54
"Trimetazidine has cardioprotective function during ischemia and reperfusion."( [Protective effect of trimetazidine on rabbit myocardium during ischemia- reperfusion].
Dong, JZ; Huang, YW; Wang, J; Wei, JH; Wei, TX; Zhang, JY, 2003
)
1.35
"Trimetazidine (TMZ) has been shown to partially inhibit free fatty acid oxidation by shifting substrate utilization from fatty acid to glucose. "( Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Calori, G; Fragasso, G; Lopaschuk, GD; Margonato, A; Monti, L; Palloshi, A; Piatti Md, PM; Puccetti, P; Setola, E, 2003
)
2.02
"Trimetazidine has been assessed in several double-blind randomised studies as a treatment of ischaemic heart disease or as an agent given prior to or during percutaneous transluminal coronary angioplasty, coronary artery bypass grafting and thrombolysis to prevent or limit ischaemia/reperfusion damage in the heart."( Cardioprotective effects of trimetazidine: a review.
Marzilli, M, 2003
)
1.33
"Trimetazidine (TMZ), which has been used in numerous experimental studies, is applied nowadays with the aim of reducing myocardial ischemia. "( Effects of trimetazidine and selenium on high-frequency fatigue in isolated rat diaphragm muscle.
Emre, M; Karayaylali, I; San, M,
)
1.96
"Trimetazidine has no hemodynamic/antithrombotic actions. "( The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury.
Ambrosio, G; Giraldez, R; Kuppusamy, P; Tritto, I; Wang, P; Zweier, JL, 2005
)
2.09
"Trimetazidine has been reported, in some studies, to be better tolerated than combined anti-anginal therapy; however it is not considered in published guidelines."( Trimetazidine for stable angina.
Ciapponi, A; Harrison, J; Pizarro, R, 2005
)
2.49
"Trimetazidine has been shown to have anti-ischemic properties by improving exercise tolerance without haemodynamic effects and direct cyto-protective effects on the myocardium. "( [Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
, 2005
)
2.09
"Trimetazidine (TMZ) has antioxidant properties and may affect the utilization of oxygen radicals."( Effects of trimetazidine on lipid peroxidation, antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale.
Atalay, C; Bayram, E; Kocatürk, H; Yücel, O,
)
1.24
"Trimetazidine has been shown to improve symptoms and LV ejection fraction and to have a beneficial effect on the inflammatory profile and endothelial function in these patients."( Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez, V; Bouzas-Mosquera, A; Kaski, JC, 2006
)
1.49
"1. Trimetazidine has a direct anti-ischaemic effect on the myocardium without altering the rate x pressure product or coronary blood flow. "( Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
Cokkinos, D; Dargie, H; Detry, JM; Mathes, P; Pennaforte, S; Sellier, P, 1994
)
2.35
"Trimetazidine (TMZ) has recently been shown to improve anginal symptoms without modifying haemodynamic variables."( Myocardial cytoprotection during percutaneous transluminal coronary angioplasty.
Buck, T; Kober, G; Pennaforte, S; Sievert, H; Vallbracht, C, 1993
)
1.01
"Trimetazidine (TMZ) has been described as a new antiischemic agent. "( Effect of trimetazidine on postischemic regional myocardial stunning in the halothane-anesthetized dog.
Arvieux, C; Cannet, E; de Lorgeril, M; Ferrera, R; Forrat, R; Guidollet, J; Hadour, G; Lehot, JJ; Sebbag, L; Vedrinne, C, 1996
)
2.14
"Trimetazidine has an original cytoprotective mode of action reducing oxygen demand without altering heart activity."( [New concepts in the therapy of diabetic cardiopathies].
Pogátsa, G, 1997
)
1.02
"Trimetazidine (TMZ) has been postulated to be protective against renal damage from oxygen free radicals."( Lipid peroxidation after cold storage and normothermic reperfusion: the effect of trimetazidine.
Baumert, H; Caritez, JC; Carretier, M; Eugene, M; Germonville, T; Hauet, T; Journe, F; Mothes, D; Tillement, JP, 1998
)
1.25
"Trimetazidine has an anti-ischemic effect in angina pectoris. "( Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
Buxton, DB; Coyle, KB; Hansen, HW; Mody, FV; Mohiuddin, IH; Schelbert, HR; Singh, BN; Sumida, R, 1998
)
3.19
"Trimetazidine (TMZ) has been reported to exert a protective action against normothermic ischemia and reperfusion injury in several experimental and clinical studies."( Efficiency of trimetazidine in renal dysfunction secondary to cold ischemia-reperfusion injury: a proposed addition to University of Wisconsin solution.
Carretier, M; Eugene, M; Goujon, JM; Hauet, T; Tallineau, C; Tillement, JP, 1998
)
1.38
"Trimetazidine has been shown to improve anginal symptoms and exercise tolerance in patients with coronary artery disease (CAD). "( Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study.
Allal, J; Harpey, C; Ourbak, P; Pornin, M; Sellier, P, 1994
)
2.06
"Trimetazidine since it has antioxidant properties was found to be effective in patients with low thiol disulfide ratios."( [Myocardial cytoprotection with trimetazidine in patients with ischemic heart disease during surgical stress].
Afanas'eva, IV; Goncharova, LL; Miroshnichenko, AG; Petrash, VV; Pokrovskaia, LA, 1999
)
1.31
"Trimetazidine has been shown to improve anginal symptoms without altering hemodynamic variables in patients with coronary artery disease. "( Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance.
Chierchia, SL; Dabrowski, P; Fragasso, G; Leonardo, F; Pagnotta, P; Rosano, GM; Rossetti, E, 1999
)
2.11
"Trimetazidine has been suggested to exert anti-ischemic properties on myocardium without affecting myocardial oxygen consumption or supply."( Metabolic management of coronary heart disease: adjunctive treatment with trimetazidine decreases QT dispersion in patients with a first acute myocardial infarction.
Dimitroula, V; Karanikis, P; Kountouris, E; Pappa, E; Pappas, K; Siogas, K; Tzimas, T, 2001
)
1.26
"Trimetazidine (TMZ) has recently been shown to improve anginal symptoms without altering haemodynamic variables. "( Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine.
Buck, T; Kober, G; Sievert, H; Vallbracht, C, 1992
)
1.95
"Trimetazidine has been shown to have an antianginal effect, increasing exercise capability without producing any significant change of heart rate or systolic blood pressure. "( Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study.
Dalla-Volta, S; Della-Valentina, P; Desideri, A; Maraglino, G; Viena, P, 1990
)
2.08
"Trimetazidine (TMZ) has been shown to have anti-ischaemic properties improving exercise tolerance without haemodynamic effects. "( Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.
Barat, JL; Bonnet, J; Boussens, B; Bricaud, H; Brottier, L; Combe, C, 1990
)
1.72

Actions

Trimetazidine was able to inhibit the extracellular glutamate accumulation, which represents the first step of the excitotoxic phenomenon. The drug did not produce any behavioural impairment as revealed by the mouse rotarod.

ExcerptReferenceRelevance
"Trimetazidine was able to inhibit the extracellular glutamate accumulation, which represents the first step of the excitotoxic phenomenon."( Anti-excitotoxic activity of trimetazidine in the retina.
Bonne, C; D'Aldin, C; Maurin, L; Muller, A; Payet, O, 2004
)
1.34
"Trimetazidine did not produce any behavioural impairment as revealed by the mouse rotarod."( Pharmacological investigation of trimetazidine in models of inflammation, pain and gastric injury in rodents.
Abdel-Salam, OM; El-Batran, S, 2005
)
1.33
"Trimetazidine may produce obvious therapeutic effect on insulin resistance in CHD patients."( [Effect of trimitazidine on insulin resistance in patients with coronary heart disease].
Cai, JS; Peng, ZJ, 2006
)
1.78
"Trimetazidine-associated increase in 99mTc-sestamibi uptake in infarcted but viable myocardial areas is probably related to an improvement in mitochondrial oxidative metabolism that is essential to 99mTc-sestamibi retention. "( Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium.
Campa, PP; Ciavolella, M; Greco, C; Scopinaro, F; Tanzilli, G; Tavolaro, R,
)
1.96

Treatment

Trimetazidine (TMZ) pretreatment protects cardiomyopathy. Treatment with trimetazidine worsened Parkinson's disease in 12 patients.

ExcerptReferenceRelevance
"Trimetazidine (TMZ) pretreatment protects cardiomyocytes during cardiac surgery. "( Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Dai, ZL; Gao, WL; Li, Y; Lin, J; Lin, M; Song, YF; Tian, Y; Wang, P; Wang, Q, 2021
)
3.51
"Trimetazidine treatment, compared to placebo, reduced the number of weekly angina attacks (mean difference: –1.84, 95% CI: –2.39 to –1.30; p<0.0001) and reduced weekly nitroglycerin consumption (–1.65, 95% CI: –2.17 to –1.14; p<0.0001) in randomized trials."( Clinical effect of various trimetazidine formulations in chronic coronary syndrome
Herold, Z; Nagy, VL, 2020
)
1.58
"Trimetazidine treatment is likely to improve the left ventricular remodeling, symptoms of angina and myocardial ischemia."( Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial.
He, J; Jin, C; Li, Y; Luan, Y; Wang, M; Wu, L; Zhang, W, 2020
)
1.67
"Trimetazidine treatment significantly (p < 0.05) improved glucose metabolism, lowered HbA1c (7.1 ± 1.1% vs 6.6 ± 1.0%), glucose levels (7.7 ± 2.1 mmol/l vs 6.9 ± 1.6 mmol/l) and decreased arterial stiffness (pulse wave velocity 11.2 ± 2.1 m/s vs 10.4 ± 2.2 m/s). "( Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes.
Gaszner, B; Hild, G; Kónyi, A; Meiszterics, Z; Sárszegi, Z, 2017
)
2.16
"Trimetazidine-treatment led to a mild shift in substrate preference toward carbohydrates as an oxidative fuel source in obese mice, evidenced by an increase in the respiratory exchange ratio."( Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
Fillmore, N; Ilkayeva, OR; Jaswal, JS; Keung, W; Koves, TR; Lopaschuk, DG; Lopaschuk, GD; Mori, J; Muoio, DM; Ussher, JR; Wagg, CS; Zhang, L, 2014
)
1.37
"Trimetazidine treatment effectively reduced the incidence of SR and MACCEs after DES implantation at the 1-year follow-up."( Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study.
Chen, J; Chen, Y; Han, Y; Jin, J; Liu, J; Tian, F; Wang, J; Zhou, S, 2014
)
2.16
"Trimetazidine treatment significantly improved inflammation, oxidative stress and membrane destruction in LPS-induced sepsis. "( Appreciation of trimetazidine treatment in experimental sepsis rat model.
Bilgi, C; Comert, B; Inal, V; Ocal, R; Tanoglu, A; Yamanel, L, 2015
)
2.21
"Trimetazidine treatment did not alter the contents of CrP, ATP, ADP, AMP and TAN, but significantly increased atrial eNOS expression (P < 0.05), decreased plasma vWF (P < 0.01) and increased plasma NOx concentration."( [Effects of chronic trimetazidine treatment on atrial energy metabolism in a canine model of chronic atrial fibrillation].
Cao, Y; Dong, G; Fu, SB; Han, W; Huo, H; Li, WM; Wei, N; Yang, SS; Zhou, G; Zhou, HY, 2008
)
1.39
"Trimetazidine treatment affect chronic AF induced disturbance in energy metabolism but may improve endothelial function through a NOx depended manner."( [Effects of chronic trimetazidine treatment on atrial energy metabolism in a canine model of chronic atrial fibrillation].
Cao, Y; Dong, G; Fu, SB; Han, W; Huo, H; Li, WM; Wei, N; Yang, SS; Zhou, G; Zhou, HY, 2008
)
2.11
"Trimetazidine treatment was associated with a significant improvement of cardiac function and physical tolerance. "( The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy.
Cui, LQ; Maharaj, P; Narraindoo, S; Tang, YS; Yin, XG; Zhang, J; Zhao, P, 2013
)
2.19
"Trimetazidine treatment was associated with a significant improvement of left ventricular function and the remodelling process."( Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.
Barsotti, A; Di Napoli, P; Taccardi, AA, 2005
)
1.32
"Trimetazidine treatment limited the increase in the n-6/n-3 ratio and prevented the decrease in DHA content in mitochondrial membranes."( Cardiac mitochondrial alterations induced by insulin deficiency and hyperinsulinaemia in rats: targeting membrane homeostasis with trimetazidine.
Bescond-Jacquet, A; Grynberg, A; Ovide-Bordeaux, S, 2005
)
1.25
"Trimetazidine pretreatment apparently decreased apoptotic index (11.37% +/- 2.53%, P < 0.01 vs the sham or control) and MDA concentration (5.49 +/- 0.74 micromol/L, P > 0.05 vs sham, P < 0.01 vs control), and increased SOD levels (88.81 +/- 2.81 microU/L, P > 0.05 vs sham, P < 0.01 vs control)."( Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion.
Al-Ghazali, R; Ruixing, Y; Wenwu, L, 2007
)
2.5
"In trimetazidine-treated patients, a significant increase of the left ventricle ejection fraction was also detected (LVEF P < 0.001 at 48 months)."( Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
Barsotti, A; Di Giovanni, P; Di Napoli, P; Gaeta, MA; Taccardi, AA, 2007
)
2.3
"Trimetazidine treatment was associated with significantly better biochemical and histological markers of renal function and structure."( Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine.
Bouchier-Hayes, D; Creagh, T; Dolan, J; Lanigan, D; Tormey, W; Walshe, JJ, 1993
)
1.24
"In trimetazidine-treated cells, arachidonic acid incorporation was increased in the phospholipid, but not in other lipid fractions."( Is the cytoprotective effect of trimetazidine associated with lipid metabolism?
Grynberg, A; Lucien, A; Sentex, E; Sergiel, JP, 1998
)
1.1
"Trimetazidine treatment attenuated the extent of myocardial damage produced by global ischemia."( Coronary artery constriction in rats: necrotic and apoptotic myocyte death.
Anversa, P; Baldini, A; Kajstura, J; Leri, A; Li, B; Liu, Y; Olivetti, G, 1998
)
1.02
"Trimetazidine pretreatment reduced the liver injury."( Trimetazidine ameliorates the hepatic injury associated with ischaemia-reperfusion in rats.
Cherrah, Y; Elimadi, A; Lamchouri, F; Morin, D; Settaf, A; Tillement, JP, 1999
)
2.47
"Trimetazidine treatment reduced cytolysis (p < 0.05 on day 1, day 3, day 5), increased liver ATP content and limited the increase of reduced and oxidized gluthatione in the plasma during reperfusion."( [Trimetazidine prevents ischemia-reperfusion injury in hepatic surgery under vascular clamping].
Bellouch, M; Morin, D; Settaf, A; Tillement, JP; Zaim, N,
)
1.76
"Pretreatment of trimetazidine in all doses showed an ameliorating effect on biochemical alteration induced by PTZ treatment."( Anticonvulsant and antioxidant actions of trimetazidine in pentylenetetrazole-induced kindling model in mice.
Bharal, N; Jain, S; Khurana, S; Mediratta, PK; Sharma, KK, 2011
)
0.97
"Treatment with trimetazidine (TMZ), 1-[2,3,4-trimethoxybenzyl] piperazine, dihydrochloride, improves cardiac function and ameliorates endothelial dysfunction. "( Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats.
Cho, BJ; Choi, SH; Jang, HC; Kang, SM; Kim, YB; Lee, MJ; Lim, S; Park, HS; Park, KS; Shin, H; Yoon, JW, 2013
)
1.05
"Treatment with trimetazidine was well tolerated."( Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris.
Almazov, VV; Kazarin, VV; Nifontov, EM; Rudomanov, OG; Shlyakhto, EV; Vakhrameyeva, IV; Vakhrameyeva, NV; Zakharov, DV, 2002
)
0.96
"Treatment with trimetazidine per os afforded a significant protection of the electroretinogram against the ischemic as well as the excitotoxic insult as an antioxidant (dimethylthiourea) and a nitric oxide synthase inhibitor (nitroarginine) did."( Anti-excitotoxic activity of trimetazidine in the retina.
Bonne, C; D'Aldin, C; Maurin, L; Muller, A; Payet, O, 2004
)
0.95
"Treatment with trimetazidine added to the usual treatment for up to 18 months was well tolerated and induced a functional improvement in patients with dilated cardiomyopathy. "( Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.
Barsotti, A; Di Napoli, P; Taccardi, AA, 2005
)
0.95
"Treatment with trimetazidine worsened previously diagnosed Parkinson's disease in 12 patients, and gait disorders coupled with disequilibrium was observed in 15 patients."( Trimetazidine induces parkinsonism, gait disorders and tremor.
Carrera, N; López de Munain, A; Martí Massó, JF; Martí, I; Poza, JJ,
)
1.91
"Treatment with trimetazidine significantly decreased left ventricular end-systolic volume (from 98 +/- 36 ml to 81 +/- 27 ml, p = 0.04) and increased EF from 36 +/- 7% to 43 +/- 10% (p = 0.002)."( A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
Alfieri, O; Calori, G; Fragasso, G; Margonato, A; Pala, M; Palloshi, A; Puccetti, P; Rossodivita, A; Silipigni, C, 2006
)
0.96

Toxicity

SBP combined with trimetazidine significantly improved the clinical efficacy and indices of cardiac function. 1219 (40·9%) of 2983 patients in the trimeazidine group and 1230 (41·1%) of 2990 patients in a placebo group had serious treatment-emergent adverse events.

ExcerptReferenceRelevance
"The mechanisms of the adverse effects of free fatty acids on the ischemic-reperfused myocardium are not fully understood."( Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts.
Bettaieb, A; Filomenko, R; Gambert, S; Moreau, D; Opie, LH; Rochette, L; Vergely, C, 2006
)
0.33
"Nephrotoxicity is a dose-limiting side effect of cisplatin (CSP)."( The protective effect of trimetazidine against cisplatin-induced nephrotoxicity in rats.
Attia, GM; El-Sherbeeny, NA, 2016
)
0.74
" Several clinical outcomes [early/short-term all-cause mortality, long-term all-cause mortality, total major adverse cardiac events (MACE), recurrent nonfatal MI, in-hospital adverse events, target vessel revascularization (TVR), and coronary artery bypass graft (CABG)] were analyzed by the intention-to-treat principle."( Efficacy and Safety of Adjunctive Trimetazidine Therapy for Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.
Hu, C; Li, Y; Qin, S; Wang, D; Zhang, D; Zhang, P,
)
0.41
" In most patients, the tolerability of trimetazidine was rated as excellent to good, with a low incidence of adverse events."( Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes.
Gaszner, B; Hild, G; Kónyi, A; Meiszterics, Z; Sárszegi, Z, 2017
)
0.99
" Meta-analysis showed that, when compared with conventional therapy, SBP combined with trimetazidine significantly improved the clinical efficacy and indices of cardiac function (including increasing left ventricular ejection fraction [LVEF] and 6-minute walk distance [6-MWD], decreasing left ventricular end-diastolic diameter [LVEDD] and left ventricular end-systolic diameter [LVESD]) without serious adverse reactions."( Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Lu, X; Ma, X; Wang, J; Wen, J; Yang, Y; Zhang, L; Zhao, Y, 2018
)
0.94
" 1219 (40·9%) of 2983 patients in the trimetazidine group and 1230 (41·1%) of 2990 patients in the placebo group had serious treatment-emergent adverse events."( Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
Challeton, JP; Correges, A; Danchin, N; Ferrari, R; Ford, I; Fox, K; Tendera, M; Widimský, P, 2020
)
1.14

Pharmacokinetics

The relative bioavailability and pharmacokinetic characteristics of two modified release formulations of 35 mg trimetazidine were compared in healthy Bangladeshi male volunteers. The study aims to assess the bioequivalence of test and reference formulations.

ExcerptReferenceRelevance
"Objectives - To study the effect of age and renal function on the pharmacokinetic profile of a modified release tablet of trimetazidine (TMZ MR 35 mg) administered twice daily."( Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure.
Barré, J; Brakenhoff, JP; Ledudal, P; Oosterhuis, B; Sollie, FA; Tran, D; Wilkens, G, 2003
)
0.77
" The relative bioavailability and pharmacokinetic characteristics of two modified release formulations of 35 mg trimetazidine, one as the test product (Metacard MR) and one as the reference product, were compared in healthy Bangladeshi male volunteers."( Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers.
Akter, KA; Al Maruf, A; Begum, B; Chowdhury, MM; Harun, S; Hasnat, A; Iqbal, N; Latif, AH; Shohag, MH; Ullah, MA, 2011
)
0.82
"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70."( [Pharmacokinetics and bioequivalence of domestic trimetazidine formulations].
Li, J; Lin, Y; Liu, WF; Ma, CS; Suo, W; Wu, W; Yang, KX; Zhao, GP, 2012
)
0.86
" The optimized formula (PO) was subjected to stability study and pharmacokinetic assessment on New Zealand rabbits."( Trimetazidine Dihydrochloride Pulsatile-Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation.
Abdelbary, GA; Abu-Elyazid, SK; Amin, MM; Othman, AI, 2021
)
2.06
" The pharmacokinetics study confirmed the pulsatile-release pattern with Cmax of 206."( Trimetazidine Dihydrochloride Pulsatile-Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation.
Abdelbary, GA; Abu-Elyazid, SK; Amin, MM; Othman, AI, 2021
)
2.06
"This study aims to assess the bioequivalence of test and reference formulations of trimetazidine dihydrochloride in healthy Chinese volunteers under fasting and fed conditions, and to determine the effect of food on the pharmacokinetic profiles of both formulations."( Bioequivalence and Pharmacokinetic Profiles of 2 Trimetazidine Modified-release Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects.
Huang, J; Huang, X; Wang, J; Yang, Y; Zhang, B, 2023
)
1.39

Compound-Compound Interactions

This systematic review was designed to provide rigorous therapeutic efficacy and safety evidence on the use of SBP combined with trimetazidine in elderly patients with heart failure (HF) secondary to ischaemic cardiomyopathy (ICM)

ExcerptReferenceRelevance
"Four weeks of treatment with trimetazidine in combination with conventional antiangina drugs leads to a longer delay to development of 1 mm ST depression (ischemia threshold), significant lengthening of total duration of treadmill exercise, increased total work, and longer delay to angina theshold."( [Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study].
Domzal-Bochenska, M; Elikowski, W; Gajos, G; Kaluza, G; Kulon, I; Kuźniak, M; Pachocki, R; Paradowski, A; Szwed, H; Szydlowski, Z; Szymczak, K; Wator-Brzezińska, A, 2000
)
0.9
" This study investigates the efficacy and acceptability of low dose diltiazem in combination with trimetazidine for the treatment of stable angina."( Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine.
Manchanda, SC, 2003
)
0.76
"In a 28-day, randomized, double blind study, treatment with 90 mg diltiazem in combination with 60 mg trimetazidine or placebo per day was compared in 50 patients with stable angina."( Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine.
Manchanda, SC, 2003
)
0.75
"To investigate the effect of compound Danshen Droplet-pill (DS) combined with trimetazidine (TMZ) in treating senile unstable angina pectoris (SUAP)."( [Observation on effect of compound danshen droplet-pill combined with trimetazidine in treating senile unstable angina pectoris].
Ma, HJ; Qiu, ZX; Wang, DF, 2005
)
0.79
" Conclusion DS combined with TMZ is superior in treating SUAP."( [Observation on effect of compound danshen droplet-pill combined with trimetazidine in treating senile unstable angina pectoris].
Ma, HJ; Qiu, ZX; Wang, DF, 2005
)
0.56
"Data of treatment of 45 patients with stable angina combined with type 2 diabetes mellitus are presented."( [Correction of episodes of transitory myocardial ischemia with trimetazidine in patients with ischemic heart disease combined with type 2 diabetes mellitus].
Makolkin, VI; Mikova, NV; Petriĭ, VV, 2007
)
0.58
" The use of complex therapy with emoxipin and preductal in a combination with antiarrhythmic agents potentated the action of these preparations."( [The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents].
Chibisov, SM; Kairakina, TN; Kotliarov, AA; Kulikov, SI; Mosina, LM, 2007
)
0.34
"Based on retrospective analysis of 2446 in-patient cards, autopsy protocols, outpatient medical documentation, prevalence and features of clinical manifestation of cardiorespiratory pathology (CRP): coronary heart disease (CHD) combined with chronic obstructive pulmonary disease (COPD)--1 stage of study, and also (after randomization and forming of main and control groups), efficiency of myocardial cytoprotector trimetazidin (TMZ) at its long-term use (1 year) in combined therapy (2 stage of study): 135 CHD patients (stable exertional angina functional class II-III: 92 and 43 persons respectively) with COPD of medium severe (111 persons) and severe course (24 persons), were studied."( [Clinicopathogenetic features of coronary heart disease combined with chronic obstructive pulmonary diseases and efficiency of therapy with trimetazidin].
Baksheev, VI; Kolomoets, NM; Uvaĭsova, KU, 2008
)
0.35
"A hollow fiber-based liquid phase microextraction strategy combined with high-performance liquid chromatography was evaluated for the quantitative determination of trimetazidine in human plasma."( Hollow fiber-based liquid membrane microextraction combined with high-performance liquid chromatography for extraction and determination of trimetazidine in human plasma.
Bi, K; Chen, X; Liu, D; Lv, J; Ye, J; Zhao, X, 2013
)
0.79
"To investigate the effects of atorvastatin combined with trimetazidine on periprocedural myocardial injury and serum inflammatory mediators in unstable angina pectoris (UAP) patients following percutaneous coronary intervention (PCI) treatment."( Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention.
Cui, W; Du, H; Hao, J; Li, WW; Liu, F; Lu, JC; Yang, XC; Zhao, ZF, 2015
)
0.93
" The control group had 42 patients were treated with atorvastatin alone, while the experimental group had 48 cases treated with atorvastatin combined with trimetazidine."( Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention.
Cui, W; Du, H; Hao, J; Li, WW; Liu, F; Lu, JC; Yang, XC; Zhao, ZF, 2015
)
0.89
"No unexpected symptom was found in patients with large dose atorvastatin combined with large dose trimetazidine."( Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention.
Cui, W; Du, H; Hao, J; Li, WW; Liu, F; Lu, JC; Yang, XC; Zhao, ZF, 2015
)
0.91
" This systematic review was designed to provide rigorous therapeutic efficacy and safety evidence on the use of SBP combined with trimetazidine in elderly patients with heart failure (HF) secondary to ischaemic cardiomyopathy (ICM)."( Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Lu, X; Ma, X; Wang, J; Wen, J; Yang, Y; Zhang, L; Zhao, Y, 2018
)
0.92
"Relevant randomized controlled trials (RCTs) investigating the clinical efficacy of SBP combined with trimetazidine in treating ICM-associated HF were widely searched in electronic databases, including PubMed, Cochrane library, EMBASE, CBM, CNKI, VMIS, and Wanfang up to January 1, 2018."( Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Lu, X; Ma, X; Wang, J; Wen, J; Yang, Y; Zhang, L; Zhao, Y, 2018
)
0.93
" Meta-analysis showed that, when compared with conventional therapy, SBP combined with trimetazidine significantly improved the clinical efficacy and indices of cardiac function (including increasing left ventricular ejection fraction [LVEF] and 6-minute walk distance [6-MWD], decreasing left ventricular end-diastolic diameter [LVEDD] and left ventricular end-systolic diameter [LVESD]) without serious adverse reactions."( Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Lu, X; Ma, X; Wang, J; Wen, J; Yang, Y; Zhang, L; Zhao, Y, 2018
)
0.94
"This work provides evidence of the benefit of SBP combined with trimetazidine for the treatment of HF secondary to ICM."( Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Lu, X; Ma, X; Wang, J; Wen, J; Yang, Y; Zhang, L; Zhao, Y, 2018
)
0.95
"To explore the effects of trimetazidine combined with exercise on EC and anti-fatal stress ability, and illustrate the underlying mechanism."( Trimetazidine combined with exercise improves exercise capacity and anti-fatal stress ability through enhancing mitochondrial quality control.
Dun, Y; Jiang, L; Liu, S; Xie, M; Zhang, W, 2019
)
2.26
" Fatal stress experiments successfully induced skeletal muscle damage, including increased creatine kinase activity, myofibrosis, and impaired antioxidative enzyme system, all those were significantly alleviated by trimetazidine supplementation combined with AE precondition (P < 0."( Trimetazidine combined with exercise improves exercise capacity and anti-fatal stress ability through enhancing mitochondrial quality control.
Dun, Y; Jiang, L; Liu, S; Xie, M; Zhang, W, 2019
)
2.14
" Enhancing MQC may be a key mechanism of AE combined with trimetazidine that improves EC and anti-fatal stress ability."( Trimetazidine combined with exercise improves exercise capacity and anti-fatal stress ability through enhancing mitochondrial quality control.
Dun, Y; Jiang, L; Liu, S; Xie, M; Zhang, W, 2019
)
2.2
" However, the clinical evidence CDDP combined with TMZ for treating UAP is not sufficient."( Compound danshen dripping pills combined with trimetazidine in treating unstable angina pectoris: Protocol for a systematic review of randomized controlled trials.
Han, L; Liu, J; Wang, B; Wang, C; Yao, D; Zhang, E; Zhang, P, 2019
)
0.77
"We searched for randomized controlled trials testing CDDP combined with TMZ for the treatment of UAP in Chinese National Knowledge Infrastructure database, VIP database, Chinese Biological and Medicine database, Wangfang database, MEDLINE, EMBASE, Cochrane Library, and Web of Science."( Compound danshen dripping pills combined with trimetazidine in treating unstable angina pectoris: Protocol for a systematic review of randomized controlled trials.
Han, L; Liu, J; Wang, B; Wang, C; Yao, D; Zhang, E; Zhang, P, 2019
)
0.77
"This systematic review will be provided up-to-date clinical evidence to evaluate the effectiveness and safety of CDDP combined with TMZ for the treatment of parents with UAP."( Compound danshen dripping pills combined with trimetazidine in treating unstable angina pectoris: Protocol for a systematic review of randomized controlled trials.
Han, L; Liu, J; Wang, B; Wang, C; Yao, D; Zhang, E; Zhang, P, 2019
)
0.77
"This experiment aimed to study the effect of trimetazidine combined with perindopril on NT-proBNP levels in rats with dilated cardiomyopathy (DCM)."( Effect of trimetazidine combined with perindopril on NT-proBNP level in rats with dilated cardiomyopathy.
Chen, L; Lin, J; Yan, J; Zhong, B, 2020
)
1.22
"To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD)."( Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
Fu, B; Ma, S; Zhang, X, 2021
)
1.21
"To evaluate the myocardial protection of Ivabradine (IBD) combined with Trimetazidine (TMZ) in patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI), magnetic resonance imaging (MRI) images under convolutional neural network (CNN) algorithm were used."( Protection of Ivabradine Combined with Trimetazidine on Myocardial Injury after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease Evaluated by Magnetic Resonance Image under Convolutional Neural Network.
Chen, C, 2021
)
1.12
" For patients with CAD, IBD combined with TMZ after PCI can effectively play the role of anti-inflammatory and antioxidative damage and improve intradermal function."( Protection of Ivabradine Combined with Trimetazidine on Myocardial Injury after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease Evaluated by Magnetic Resonance Image under Convolutional Neural Network.
Chen, C, 2021
)
0.89
"Nicorandil in combination with trimetazidine can be considered as an effective and potential treatment strategy in reducing the rate of MACE in patients with CHD in the Chinese population."( Clinical Implications of Nicorandil Combined with Trimetazidine in Patients with Coronary Heart Disease: A Real-World Observational Study.
Li, N; Liu, J; Qiu, L; Shen, L; Shu, H; Zhou, N, 2022
)
1.26
" In order to explore the demand for cardiovascular disease treatment, make up for the lack of chronic diseases affecting people's physical harm, and improve the success rate of cardiovascular disease treatment, a method to observe the efficacy and myocardial remodeling of trimetazidine combined with metoprolol in elderly patients with coronary heart disease and heart failure based on integrated traditional Chinese and Western medicine was proposed."( Observation of Curative Effect of Trimetazidine Combined with Metoprolol in Elderly Patients with Coronary Heart Disease Complicated with Heart Failure and the Effect of Myocardial Remodeling by Integrated Traditional Chinese and Western Medicine.
Lu, Y; Ni, H; Shi, H; Sun, Y; Wang, F, 2022
)
1.18

Bioavailability

The method was successfully applied to study the relative bioavailability of trimetazidine hydrochloride tablets in healthy Chinese volunteers. The authors investigated the effect of being under a fasting or fed state at the time of drug intake on the bioavailability.

ExcerptReferenceRelevance
" By diminishing the bioavailability of free radicals, trimetazidine lessens all their toxic effects: trimetazidine acts on the inactivation of enzymatic membrane proteins (which induces ATP over-reduction, creatine phosphokinase and lactate release outside the cell and electrolyte shifts); trimetazidine corrects the elevation of passive membrane permeability (increased by free radical-induced peroxidation of unsaturated membrane lipids); it antagonises free radical-induced stimulations of phospholipase A2 and thromboxane synthetase."( [Cellular disorders induced by ischemia. The effect of trimetazidine].
Labrid, C, 1986
)
0.77
" The method was successfully applied to study the relative bioavailability of trimetazidine hydrochloride tablets in healthy Chinese volunteers and the pharmacokinetic parameters of the reference and test tablets were compared."( Liquid chromatography-tandem mass spectrometry method for the determination of trimetazidine in human plasma.
Dai, L; Fan, H; Wang, GJ; Xiao, da W; Zhu, Y; Zou, J, 2008
)
0.8
" Finally, in vivo bioavailability study was done on human volunteers."( Floating tablet of trimetazidine dihydrochloride: an approach for extended release with zero-order kinetics.
Abdelbary, A; Ali, AA; El-Gazayerly, ON; El-Gendy, NA, 2010
)
0.69
" The relative bioavailability and pharmacokinetic characteristics of two modified release formulations of 35 mg trimetazidine, one as the test product (Metacard MR) and one as the reference product, were compared in healthy Bangladeshi male volunteers."( Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers.
Akter, KA; Al Maruf, A; Begum, B; Chowdhury, MM; Harun, S; Hasnat, A; Iqbal, N; Latif, AH; Shohag, MH; Ullah, MA, 2011
)
0.82
" The authors investigated the effect of being under a fasting or fed state at the time of drug intake on the bioavailability of trimetazidine 35-mg MR tablets in a randomized, open-label, crossover, 2-arm, 4-period, 2-sequence bioequivalence study design with a 14-day washout period."( Food effect on bioavailability of modified-release trimetazidine tablets.
Erol, D; Ozbay, L; Unal, DO, 2012
)
0.84
" The relative bioavailability of domestic formulation was (102."( [Pharmacokinetics and bioequivalence of domestic trimetazidine formulations].
Li, J; Lin, Y; Liu, WF; Ma, CS; Suo, W; Wu, W; Yang, KX; Zhao, GP, 2012
)
0.63
"01-fold enhancement in the oral bioavailability vis-à-vis the marketed formulation (Vastarel MR®)."( Mucoadhesive elementary osmotic pump tablets of trimetazidine for controlled drug delivery and reduced variability in oral bioavailability.
Ahmad, A; Ahmad, FJ; Alam, N; Ali, A; Aqil, M; Beg, S; Rizwan, M, 2015
)
0.67
"85% relative bioavailability compared to TMZ solution."( Trimetazidine Dihydrochloride Pulsatile-Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation.
Abdelbary, GA; Abu-Elyazid, SK; Amin, MM; Othman, AI, 2021
)
2.06

Dosage Studied

Study was conducted in order to assess the activity of trimetazidine dosed at 60 mg/day in patients presenting degenerative loss of hearing. The delayed T(max), decreased C(max) and K(a), unaltered bioavailability, and prolonged t(1/2) and MRT indicated a slow and prolonged release.

ExcerptRelevanceReference
"This study was conducted in order to assess the activity of trimetazidine dosed at 60 mg/day in patients presenting degenerative loss of hearing."( [Trimetazidine and degenerative deafness. Effect on hearing and integration].
Bebear, JP; Bordes, LR; Haguenauer, JP; Jacquot, M; Mercier, J; Morgon, A; Pech, A; Romanet, P; Thomassin, JM; Wayoff, M, 1990
)
1.43
"This multicenter controlled double-blind study versus placebo was carried out in order to determine in which types of tinnitus trimetazidine dosed at 60 mg/day was likely to be of any therapeutical benefit."( [A multicenter double blind versus placebos study of trimetazidine in tinnitus. A clinical approach to tinnitus].
Pech, A, 1990
)
0.73
"Therefore, it was suggested that trimetazidine may be coadministered with cyclosporine A without cyclosporine A dosage adjustment."( Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients.
Albengres, E; Barre, J; Berland, Y; Brunet, P; Chauvet-Monges, AM; D'Athis, PD; Duche, JC; Dussol, B; Roumenov, D; Simon, N; Tillement, JP, 1997
)
2.02
" This drug is effective in experimental models of hypoxia induced by cyclosporin A: it restores ATP synthesis previously decreased by Ca2+ and cyclosporin A, and releases a part of Ca2+ excess accumulated by mitochondria at concentrations reached in humans at usual dosage regimens."( Potential interest of anti-ischemic agents for limiting cyclosporin A nephrotoxicity.
Albengres, E; Berland, Y; Crevat, A; d'Athis, P; Hestin, D; Jaber, K; Kessler, M; Olivier, P; Roux, F; Simon, N; Tillement, JP, 1997
)
0.3
" It is concluded that trimetazidine at an optimal dosage of 10 mg/kg/day protects mitochondria against the deleterious effects of ischemia-reperfusion."( Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function.
Cherrah, Y; Elimadi, A; Lamchouri, F; Morin, D; Sapena, R; Settaf, A; Tillement, JP, 1998
)
2.06
" The control rats received a single dosage of 2 ml/kg of corn oil (i."( Cytoprotective effects of trimetazidine in carmustine cholestasis.
Demir, A; Girgin, F; Kuralay, F; Ozutemiz, O; Tanyalcin, T; Tüzün, S, 1999
)
0.6
" The delayed T(max), decreased C(max) and K(a), unaltered bioavailability, and prolonged t(1/2) and MRT indicated a slow and prolonged release of trimetazidine dihydrochloride from guar gum three-layer matrix tablets in comparison with the immediate release tablet dosage form."( Bioavailability studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride in human volunteers.
Bhaskar, P; Karthikeyan, RS; Krishnaiah, YS; Satyanarayana, V, 2002
)
0.75
" The method is applicable to the assay of the three drugs under investigation in different dosage forms and the results are in good agreement with those obtained by the official methods (USP and JP)."( Quantitative determination of some pharmaceutical piperazine derivatives through complexation with iron(III) chloride.
Abdel-Gawad, FM; Abdel-Hamid, SM; Abou-Attia, FM; Issa, YM, 2003
)
0.32
" The proposed methods were successfully applied for the determination of trimetazidine dihydrochloride in bulk powder, laboratory-prepared mixtures containing different percentages of degradation products, and pharmaceutical dosage forms."( Determination of trimetazidine dihydrochloride in the presence of its acid-induced degradation products.
Bebawy, LI; El Sabour, SA; El Tarras, MF,
)
0.7
" After AMPA stimulation, dose-response inhibition curves showed an IC(50) of 3 microM for CNQX and 25 microM for trimetazidine."( Trimetazidine modulates AMPA/kainate receptors in rat vestibular ganglion neurons.
Chabbert, C; Dayanithi, G; Desmadryl, G; Sans, A; Travo, C, 2007
)
1.99
" This review consists of two major sections: (1) comprehensive and critical information about the pharmacological effects, mechanism of action, pharmacokinetics, side effects, and current usage of TMZ, and (2) developments in analytical techniques for the determination of the drug in raw material, pharmaceutical dosage forms, and biological samples."( Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.
Onay-Besikci, A; Ozkan, SA, 2008
)
1.79
" T4 and T8 tablets contained the least polymer concentration and complied with the dissolution requirements for controlled-release dosage forms."( Floating tablet of trimetazidine dihydrochloride: an approach for extended release with zero-order kinetics.
Abdelbary, A; Ali, AA; El-Gazayerly, ON; El-Gendy, NA, 2010
)
0.69
" The daily routine dosage was continued for 4 weeks after the procedure."( [Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention: a multi-center randomized and controlled clinical study].
Chen, YD; Du, ZM; Jiang, H; Tian, F; Wei, M; Zhao, LK, 2010
)
0.62
" The developed method was successfully used for a comparative 2 x 2 period, crossover bioequivalence study of two extended-release preparations of trimetazidine performed on 24 healthy volunteers at the steady state after multiple dosing of 35 mg twice daily for 4 days and a single 35 mg dose on the 5th day and after a single dose of 35 mg under fasting or postprandial conditions."( Application of liquid chromatography method with electrochemical detection for bioequivalence study of trimetazidine in human plasma.
Borucka, B; Grabowski, T; Gumułka, SW; Sasinowska-Motyl, M; Sawicka, R; Swierczewska, A,
)
0.55
" The new insight into chitosan-alginate matrix tablets can help to broaden the application of this type of dosage forms."( Drug release characteristics from chitosan-alginate matrix tablets based on the theory of self-assembled film.
Li, L; Mao, S; Ni, R; Shao, Y; Wang, L; Zhang, T, 2013
)
0.39
" A new formulation allowing a once-daily (od) dosage could improve patients' satisfaction and adherence."( Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice.
Glezer, MG; Vygodin, VA, 2018
)
0.74
"The goal evaluation of the effectiveness of treatment with the new TMZ OD dosage form in different regions of the Russian Federation and regional differences in the clinical characteristics of patients with coronary artery disease included in the observation, the nature of their therapy, the presence and degree of correction of modifiable risk factors in real clinical practice."( [Evaluation of the antianginal effectiveness of trimetazidine in a new dosage form for a single dose, depending on the region of the Russian Federation. ODA trial results].
Glezer, MG; Vygodin, VA, 2019
)
0.77
" The inclusion of trimetazidine in therapy in the new TMZ OD dosage form allows to obtain a pronounced antianginal effect and increase adherence to therapy."( [Evaluation of the antianginal effectiveness of trimetazidine in a new dosage form for a single dose, depending on the region of the Russian Federation. ODA trial results].
Glezer, MG; Vygodin, VA, 2019
)
1.1
" We investigated the risk of TMZ-associated parkinsonism, specifically the incidence rate, cumulative dose-response relationship, and combined effects with other parkinsonism-inducing medications."( Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study.
Jeong, KH; Kim, S; Kwon, J; Lee, E; Lee, JS; Yu, YM, 2020
)
2
"0001) in 12 months, and the frequency of nitroglycerine dosing decreased by 40."( Efficacy of trimetazidine - an inhibitor of free fatty acids oxidation in the treatment of patients with stable angina pectoris and heart failure.
Aronov, DM; Bubnova, MG, 2021
)
1
" Course dosage of doxorubicin hydrochloride was 15 mg/kg, cyclophosphamide monohydrate - 150 mg/kg, trimetazidinedihydrochloride - 42 mg/kg."( THE IMPACT OF TRIMETAZIDINE ON THE ANTHROPOMETRIC PARAMETERS OF DOXORUBICIN-CYCLOPHOSPHAMIDE MODE IN CHEMOTHERAPY-INDUCED HEART ALTERATION.
Avagimyan, A; Kakturskiy, L, 2022
)
1.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency10.00005.623417.292931.6228AID485281
thioredoxin reductaseRattus norvegicus (Norway rat)Potency44.66840.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency10.31830.004110.890331.5287AID504466
TDP1 proteinHomo sapiens (human)Potency16.36010.000811.382244.6684AID686978
thioredoxin glutathione reductaseSchistosoma mansoniPotency44.66840.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency0.11220.00527.809829.0929AID588855
gemininHomo sapiens (human)Potency0.70790.004611.374133.4983AID624297
TAR DNA-binding protein 43Homo sapiens (human)Potency15.84891.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)IC50 (µMol)100.00000.16002.03003.9000AID719674
Carnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)IC50 (µMol)100.00001.05001.05001.0500AID719720
Carnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)IC50 (µMol)100.00000.12594.244010.0000AID719719
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
long-chain fatty acid metabolic processCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
in utero embryonic developmentCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
fatty acid beta-oxidationCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
carnitine shuttleCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
carnitine metabolic processCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
positive regulation of cold-induced thermogenesisCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
response to hypoxiaCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
long-chain fatty acid metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
glucose metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
fatty acid beta-oxidationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
triglyceride metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
carnitine shuttleCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to nutrientCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to xenobiotic stimulusCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
carnitine metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
regulation of lipid storageCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to organic cyclic compoundCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
epithelial cell differentiationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
positive regulation of fatty acid beta-oxidationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
eating behaviorCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to alkaloidCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
positive regulation of innate immune responseCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to ethanolCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
aflatoxin metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
regulation of insulin secretionCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
cellular response to fatty acidCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
liver regenerationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to tetrachloromethaneCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
fatty acid metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
fatty acid metabolic processCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
fatty acid beta-oxidationCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
carnitine shuttleCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
carnitine metabolic processCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
response to blue lightCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
long-chain fatty acid transportCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
carnitine O-palmitoyltransferase activityCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
protein bindingCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
carnitine O-octanoyltransferase activityCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
acyltransferase activityCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
carnitine O-palmitoyltransferase activityCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
protein-macromolecule adaptor activityCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
identical protein bindingCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
palmitoleoyltransferase activityCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
carnitine O-palmitoyltransferase activityCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
protein bindingCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleoplasmCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
nucleolusCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
mitochondrial outer membraneCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
membraneCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
mitochondrial outer membraneCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID719671Inhibition of rat FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID719672Cytotoxicity in human KB cells2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID267729Glucose oxidation rate in isolated working rat heart at 10 uM relative to DMSO2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID719704Inhibition of CPT1A in rat myocardium2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID719673Inhibition of human FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719719Inhibition of human CPT1B2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719674Inhibition of human CPT22011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID719720Inhibition of human CPT1A2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID261291Glucose oxidation rate in isolated working hearts of Sprague-Dawley rat at 20 uM relative to DMSO2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID1355572Antitumor activity against Luc tagged human U87MG cells xenografted in BALB/c nude mouse glioblastoma orthotopic model assessed as tumor growth inhibition at 30 mg/kg, po administered daily for 5 days by MRI method relative to control2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID268133Increase in glucose oxidation rate in rat heart at 10 uM relative to control2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (895)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (5.47)18.7374
1990's146 (16.31)18.2507
2000's331 (36.98)29.6817
2010's252 (28.16)24.3611
2020's117 (13.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 100.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index100.46 (24.57)
Research Supply Index7.09 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index184.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (100.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials226 (23.30%)5.53%
Reviews136 (14.02%)6.00%
Case Studies18 (1.86%)4.05%
Observational10 (1.03%)0.25%
Other580 (59.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PROSPECTIVE ANALYSIS BETWEEN TRIMETAZIDINE Versus PLACEBO IN MYOCARDIAL INJURY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH INSTANT ANGINA AND DIABETES MELLITUS [NCT03715582]Phase 3120 participants (Anticipated)Interventional2018-10-01Recruiting
A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure [NCT03737448]Phase 130 participants (Anticipated)Interventional2018-11-28Suspended(stopped due to Lack of enrollment)
Cardiac Metabolic Modulator Treatment for Improvement of Left Ventricular Diastolic Function in Patients With Coronary Heart Disease: a Prospective, Randomized Controlled Study [NCT03887013]Phase 4226 participants (Anticipated)Interventional2019-03-25Not yet recruiting
Comprehensive Evaluation of Right Ventricular Function, Ventricular Remodeling and Micro RNA Profiling in Pulmonary Artery Hypertension: Effects of a Fatty Acid Oxidation Inhibitor [NCT02102672]Phase 225 participants (Anticipated)Interventional2014-03-31Recruiting
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis [NCT05633563]Phase 422 participants (Anticipated)Interventional2021-10-01Recruiting
Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072082]Phase 4440 participants (Anticipated)Interventional2017-06-30Not yet recruiting
Trimetazidine as an Adjunct to Enhance Clopidogrel Response: The TRACER Study. [NCT03603249]Phase 224 participants (Actual)Interventional2018-07-01Completed
Evaluation of Potential Benefits of Trimetazidine in the Management of Pateints With Metabolic Associated Fatty Liver Disease ( MAFLD) [NCT06140953]Phase 260 participants (Anticipated)Interventional2023-12-10Recruiting
Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease) [NCT03504202]10 participants (Anticipated)Interventional2019-03-01Not yet recruiting
The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension Patients in National Cardiovascular Center Harapan Kita Hospital Indonesia [NCT03273387]Phase 2/Phase 326 participants (Actual)Interventional2017-09-10Completed
Chinese People's Liberation Army General Hospital [NCT02826616]240 participants (Anticipated)Interventional2016-07-31Enrolling by invitation
Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS [NCT04788745]Phase 221 participants (Actual)Interventional2021-06-29Completed
Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial [NCT04661709]Phase 4502 participants (Anticipated)Interventional2021-03-01Not yet recruiting
[NCT01857921]290 participants (Actual)Interventional2010-12-31Completed
Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI: a Prospective,Muhicenter,Doubleblind, Double-dummy, Randomized, Controlled Trial [NCT03809273]Phase 4668 participants (Anticipated)Interventional2019-08-01Recruiting
The Efficacy and Safety of Arginine Hydrochloride Combined With Trimetazidine Hydrochloride Tablets in the Treatment of Patients With Hepatocellular Carcinoma. A Multicenter, Open, Randomized, Prospective Study [NCT03278444]Phase 3300 participants (Anticipated)Interventional2017-07-18Recruiting
The Efficacy and Safety of TACE Combined With Arginine Hydrochloride and Trimetazidine Hydrochloride Tablets in With Hepatocellular Carcinoma. A Multicenter, Open, Randomized, Prospective Study [NCT03274427]Phase 3300 participants (Anticipated)Interventional2017-07-18Recruiting
Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for Moderate to Severe Acute Respiratory Syndrome Caused by SARS-CoV-2 [NCT04760821]Phase 280 participants (Anticipated)Interventional2020-12-10Recruiting
Clinical Efficacy of Personalized Exercise Program and an Inhibitor of Fatty Acid β-oxidation in Rehabilitation of Patients With Atrial Fibrillation After Primary Radiofrequency Ablation of Pulmonary Venous Orifices [NCT04511520]72 participants (Actual)Interventional2013-07-31Completed
Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity: A Randomized Controlled Clinical Trial [NCT04702906]40 participants (Anticipated)Interventional2021-02-28Not yet recruiting
The Effects of Trimetazidine on Diabetic Nephropathy [NCT05147194]Phase 2150 participants (Anticipated)Interventional2022-01-01Not yet recruiting
Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease [NCT00282360]Phase 430 participants Interventional1999-02-28Completed
A Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic Cardiomyopathy [NCT01696370]Phase 290 participants (Anticipated)Interventional2012-04-30Recruiting
Effect Of Trimetazidine On Left Ventricular Functions and Inflammatory Markers of Patients With Type 2 Diabetes Mellitus [NCT05556005]Phase 260 participants (Anticipated)Interventional2022-09-18Recruiting
Allopurinol and Trimetazidine as a Preventive of Contrast-associated Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention [NCT05540184]Phase 4124 participants (Anticipated)Interventional2022-09-19Recruiting
Effect of Trimetazidine on Radiotherapy-induced Heart Damage in Lung Tumor Patients Treated With Stereotactic Body Radiotherapy. [NCT04939857]Phase 2/Phase 380 participants (Anticipated)Interventional2021-06-25Not yet recruiting
Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072121]Phase 4440 participants (Anticipated)Interventional2017-06-30Not yet recruiting
The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease [NCT02107144]Phase 471 participants (Actual)Interventional2014-04-30Completed
the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure [NCT03333499]Phase 180 participants (Anticipated)Interventional2017-11-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03273387 (3) [back to overview]Changes in Functional Capacity After 3 Month Intervention
NCT03273387 (3) [back to overview]Changes in Right Ventricular Ejection Fraction (RVEF %) After 3 Months Intervention
NCT03273387 (3) [back to overview]Changes in Cardiac Fibrosis After 3 Months Intervention
NCT04511520 (3) [back to overview]Atrial Fibrillation Recurrence
NCT04511520 (3) [back to overview]Atrial Fibrillation Recurrence
NCT04511520 (3) [back to overview]Atrial Fibrillation Recurrence

Changes in Functional Capacity After 3 Month Intervention

"Functional capacity assessed by SF-36 score after 3 month intervention minus with functional capacity at baseline.~SF-36 functional capacity score scale 0 to 100 with better functional capacity along with higher score." (NCT03273387)
Timeframe: Baseline and 3 months after intervention

Interventionscore on a scale (Mean)
Sugar Pill-17.73
Trimetazidine11.5

[back to top]

Changes in Right Ventricular Ejection Fraction (RVEF %) After 3 Months Intervention

Right ventricular ejection fraction (RVEF %) assessed by Cardiac MRI at 3 months intervention minus with RVEF at baseline. (NCT03273387)
Timeframe: Baseline and 3 months after intervention

Interventionpercentage of ejected blood (Mean)
Sugar Pill-2.8
Trimetazidine3.9

[back to top]

Changes in Cardiac Fibrosis After 3 Months Intervention

Native T1 mapping (ms) assessed by Cardiac MRI at 3 months intervention minus with Native T1 at baseline. (NCT03273387)
Timeframe: Baseline and 3 months after intervention

,
Interventionms (Mean)
Native T1 anteroseptalNative T1 SeptalNative T1 InferoseptalNative T1 Lateral
Sugar Pill138292294287
Trimetazidine190371-123-194

[back to top]

Atrial Fibrillation Recurrence

Number of participants with reccurrence of atrial fibrillation after RFA (NCT04511520)
Timeframe: From RFA to 3 months

InterventionParticipants (Count of Participants)
Physical Training2
Trimetazidine3
Control7

[back to top]

Atrial Fibrillation Recurrence

Number of participants with recurrence of atrial fibrillation after RFA (NCT04511520)
Timeframe: From 3 months to 6 months

InterventionParticipants (Count of Participants)
Physical Training1
Trimetazidine2
Control4

[back to top]

Atrial Fibrillation Recurrence

Number of participants with recurrence of atrial fibrillation after RFA (NCT04511520)
Timeframe: From 6 months to 12 months

InterventionParticipants (Count of Participants)
Physical Training6
Trimetazidine6
Control9

[back to top]